Regulatory Agios mulls early FDA filing for sickle cell therapy PharmaphorumAgios is planning to file its sickle cell disease candidate mitapivat with the FDA under the accelerated pathway within the next few months.RegulatoryHematologyRead full story pharminent April 1, 2026 (Last updated: April 1, 2026) Pharmaphorum Agios is planning to file its sickle cell disease candidate mitapivat with the FDA under the accelerated pathway within the next few months. RegulatoryHematologyRead full story Post navigation Previous: Biogen uplifts rare disease pipeline with $5.6bn Apellis buyoutNext: A ‘hijacked plane’: CDC, under RFK Jr.’s influence, trades science for dogma Related Stories Regulatory Third Circuit Affirms Denial of Stelara Biosimilar Injunction pharminent May 11, 2026 Regulatory Partner’s Bizengri cleared by FDA for ultra-rare cancer days after winning priority voucher pharminent May 11, 2026 Regulatory BMS’ Sotyktu secures EC approval for psoriatic arthritis pharminent May 11, 2026
